MeiraGTx (NASDAQ: MGTX) net income
MeiraGTx reported a net loss of $114.2m for fiscal 2025; in fiscal 2024 it reported a net loss of $147.8m. Earnings per share were −$1.42.
MeiraGTx's best year of the last 9 was fiscal 2017. It reported a loss in 9 of those 9 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | −$114.2m | — | −140.3% | −$1.42 |
| 2024 | −$147.8m | — | −444.1% | −$2.12 |
| 2023 | −$84.0m | — | −599.5% | −$1.49 |
| 2022 | −$129.6m | — | −814.2% | −$2.87 |
| 2021 | −$79.6m | — | −211.0% | −$1.80 |
| 2020 | −$58.0m | — | −372.6% | −$1.54 |
| 2019 | −$54.7m | — | −411.9% | — |
| 2018 | −$82.9m | — | — | — |
| 2017 | −$31.0m | — | — | — |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
MeiraGTx net income compared with its sector
By net income for its latest fiscal year, MeiraGTx ranks 350th of the 501 US health care companies with a page on Celsmar. The sector median net margin is −6.2%; that of MeiraGTx, −140.3%.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 348th | Janux Therapeutics | −$113.6m | −1,136.3% |
| 349th | IDEAYA Biosciences | −$113.7m | −52.0% |
| 350th | MeiraGTx | −$114.2m | −140.3% |
| 351st | Absci | −$115.2m | −4,113.7% |
| 352nd | Korro Bio | −$117.3m | −1,834.5% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of MeiraGTx
- How much did MeiraGTx earn in fiscal 2025?
- MeiraGTx reported a net loss of $114.2m for fiscal 2025. In fiscal 2024 it reported a net loss of $147.8m.
- What are the earnings per share of MeiraGTx?
- They were −$1.42 in fiscal 2025, compared with −$2.12 in fiscal 2024.
- Where does MeiraGTx rank in its sector by net income?
- It ranks 350th of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for MeiraGTx come from?
- From the annual report (Form 10-K) that MeiraGTx files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that MeiraGTx files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017. More on MeiraGTx: the MeiraGTx page · annual accounts · revenue · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.